The Amgen-backed neurodegenerative disease treatment specialist is set to fund new medical studies.

Vigil Neuroscience, a US-based biotechnology therapeutics developer backed by biopharmaceutical firm Amgen, has wrapped up a $90m series B round led by venture capital firm Vida Ventures.

Surveyor Capital, Orbimed, Cormorant Asset Management, Invus, Rock Springs Capital, Deep Track Capital, Atlas Venture, Northpond Venture, Hatteras Ventures, Pivotal BioVentures and Lightstone Ventures filled out the round.

Vigil Neuroscience seeks to use microglia – the principal active immune cells in the central nervous system – to treat neurodegenerative diseases.

The funding will…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn